Les Laboratoires Servier

PharmaVitae Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Report
Pages	102
ISBN Number	not applicable
Product Code	DAT09497

Price

£3,010.00
approximately: $4,470 | €3,542

PDF

PRINT £3,045 ($4,522 | €3,583)

Order above formats by FAX

Summary

Introduction

This analysis examines the historical and forecast performance for Servier in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Servier's performance against key rivals in the ethical pharmaceutical sector
See how Servier's outlook will be shaped primarily by the launch of generic copies of its largest product, Coversyl, in 2007
Evaluate Servier's strategy of expanding globally, gaining a significant presence in emerging markets

Content

Chapter 1 Executive Summary
- Key Findings
- Historical And Forecast Branded Pharmaceutical Sales Performance
- Therapeutic Strategy
- Launch And Expiry Outlook
- Externalization, Geographic And Molecule Type Strategies
- Externalization Strategy
- Geographic Strategy
- Molecule Type Strategy
- Swot Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 2 Corporate History
- Key Findings
- Background
- Key Corporate Developments
- M&A History
- Current Corporate Structure
- Branded Pharmaceuticals
- Generics
Chapter 3 Historical Performance
- Key Findings
- Introduction
- Revenue And Growth Rate Analysis, 2001-06
- Revenue And Growth Rate Vs. Peer Set
- Product Analysis, 2001-06
- Growth Drivers
- Coversyl
- Bipreterax
- Vastarel
- Growth Resistors
- Operating Revenue And Cost Analysis, 2001-06
Chapter 4 Forecast Performance
- Key Findings
- Introduction
- Revenue And Growth Rate, 2006-12
- Product Analysis, 2006-12
- Growth Drivers
- Protelos
- Procoralan
- Bipreterax
- Growth Resistors
- Coversyl
- Therapy Area Analysis, 2006-12
- Musculoskeletal
- Cardiovascular & Hematology
- Therapy Area Focus
- Launches And Expiries Analysis, 2006-12
- Launch Portfolio
- Procoralan Is Servier's Largest 'Launch' Product
- Valdoxan's Eu Launch Has Been Delayed
- Further Launches Could Boost Sales
- Core Portfolio
- Expiry Portfolio
- Launch/Core/Expiry Configuration
- Externalization Analysis, 2006-12
- Geographic Analysis, 2006-12
- Molecule Type Analysis, 2006-12
Chapter 5 Key Products And Competitors
- Key Findings
- Overview
- Cardiovascular & Hematology
- Coversyl
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Daflon
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Bipreterax
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Vastarel
- Overview
- Sales Forecast
- Newsflow
- Musculoskeletal
- Protelos
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- Future Market Assessment
- Endocrine, Metabolic & Genetic Disorders
- Diamicron
- Overview
- Sales Forecast
- Newsflow
- Competitive Landscape
- R&D Pipeline
Chapter 6 Appendix
- Ims Vs. Company-Reported Data Reconciliation
- References
- Abbreviations
- Exchange Rates
List of Tables
- Table 1: Peer Set Overview
- Table 2: Product Portfolio Overview, Sales ($M), 2006-12
- Table 3: Therapy Area Overview, Sales ($M), 2006-12
- Table 4: Launch Portfolio Overview, Sales ($M), 2006-12
- Table 5: Core Portfolio Overview, Sales ($M), 2006-12
- Table 6: Expiry Portfolio Overview, Sales ($M), 2006-12
- Table 7: Molecule Type Overview, Sales ($M), 2006-12
- Table 8: Key Products Overview
- Table 9: Coversyl: Overview
- Table 10: Coversyl: Sales Forecast ($M), 2006-12
- Table 11: Coversyl: Newsflow
- Table 12: Daflon: Overview
- Table 13: Daflon: Sales Forecast ($M), 2006-12
- Table 14: Daflon: Newsflow
- Table 15: Bipreterax: Overview
- Table 16: Bipreterax: Sales Forecast ($M), 2006-12
- Table 17: Bipreterax: Newsflow
- Table 18: Vastarel: Overview
- Table 19: Vastarel: Sales Forecast ($M), 2006-12
- Table 20: Vastarel: Newsflow
- Table 21: Protelos: Overview
- Table 22: Protelos: Sales Forecast ($M), 2006-12
- Table 23: Protelos: Newsflow
- Table 24: Diamicron: Overview
- Table 25: Diamicron: Sales Forecast ($M), 2006-12
- Table 26: Diamicron: Newsflow
- Table 27: Servier's R&D Pipeline (Phase I-Registration)
- Table 28: Exchange Rates, 2006
List of Figures
- Figure 1: Historical And Forecast Branded Pharmaceutical Sales Performance (% Cagr), Servier And Mid Pharma Peer Set
- Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
- Figure 3: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Servier
- Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Peer Set
- Figure 5: Externalization, Geographic Market And Molecule Type Dependency (%) Vs. Peer Set, 2006
- Figure 6: Externalization, Geographic Market And Molecule Type Dependency (%) Vs. Peer Set, 2012
- Figure 7: Swot Analysis of Servier
- Figure 8: Servier's Corporate Development Timeline
- Figure 9: Current Corporate Structure
- Figure 10: Revenue & Growth Rate (Branded Pharmaceutical Sales) ($M), 2001-06
- Figure 11: Branded Pharmaceutical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
- Figure 12: Growth Drivers/Resistor Products of Historical Revenue Performance ($M), 2001-06
- Figure 13: Branded Pharmaceutical Revenue ($M) And Growth Rate (%), 2006-12
- Figure 14: Top Five Products By Sales ($M), 2006
- Figure 15: Top Five Products By Sales ($M), 2012
- Figure 16: Growth Drivers And Resistors By Product, 2006-12
- Figure 17: Key Strategic Products, Sales ($M), 2006-12
- Figure 18: Branded Pharmaceutical Sales By Therapy Area ($M), 2006-12
- Figure 19: Growth Drivers And Resistors By Therapy Area ($M), 2006-12
- Figure 20: Branded Pharmaceutical Sales By Therapy Area (%), 2006-12
- Figure 21: Therapy Area Focus Compared With Peer Set (% Total Branded Pharmaceutical Sales), 2006
- Figure 22: Therapy Area Focus Compared With Peer Set (% Total Branded Pharmaceutical Sales), 2012
- Figure 23: Launch Schedule, Sales ($M), 2006-12
- Figure 24: Core Products Sales Growth ($M), 2006-12
- Figure 25: Expiry Schedule, Sales ($M), 2006-12
- Figure 26: Launch, Core And Expiry, Sales ($M), 2006-12
- Figure 27: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Servier
- Figure 28: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % of 2006 Sales), Peer Set
- Figure 29: Externalization Dependency, Sales ($M), 2006-12
- Figure 30: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
- Figure 31: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 32: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 33: Geographical Sales Breakdown ($M), 2006-12
- Figure 34: Growth Drivers And Resistors By Geography, Sales ($M), 2006-12
- Figure 35: Us Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 36: Us Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 37: Molecule Type Sales Breakdown ($M), 2006-12
- Figure 38: Growth Drivers And Resistors By Molecule Type, Sales ($M), 2006-12
- Figure 39: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
- Figure 40: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
- Figure 41: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
- Figure 42: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12